Braintree Labs Hit With Antitrust Suit Over MiraLax

By Erin Marie Daly (March 13, 2007, 12:00 AM EDT) -- A New York drug cooperative has filed a proposed class action against Braintree Laboratories Inc., accusing the drug maker of conspiring to block rivals from marketing a generic version of its laxative MiraLax and improperly listing a patent with the U.S. Patent and Trademark Office.

The lawsuit, filed Monday by Rochester Drug Co-Operative Inc. in the U.S. District Court for the District of Delaware, alleges that Braintree's anti-competitive scheme allowed it to charge supracompetitive prices for MiraLax, or polyethylene glycol 3350, an osmotic laxative that causes water to be retained in the stool.

The drug, which is used to treat occasional...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!